Literature DB >> 7438031

Lethality of nogalamycin, nogalamycin analogs, and adriamycin to cells in different cell cycle phases.

B K Bhuyan, C L Blowers, K D Shugars.   

Abstract

The drugs studied included nogalamycin and its derivative 7-con-O-methylnogalarol, dis-nogamycin and its derivative 7-con-O-methylnogarol, and Adriamycin. All of these drugs, especially at high doses, were lethal to cells in every phase of the cell cycle, indicating that they were not phase specific. However, there were significant differences in drug sensitivity of cells in different parts of the cell cycle. Nogalamycin and Adriamycin were most lethal to the cells in S phase, whereas cells in M, G1, and G2 were much less sensitive. In contrast, the nogalamycin derivative 7-con-O-methylnogalarol was almost equally lethal to cells in all phases of the cell cycle. dis-nogamycin was most lethal to cells in postmetaphase and in early S phase. Cells in mid- and late G1, late S, and G2 were much less sensitive. The pattern of sensitivity to 7-con-O-methylnogarol was different from that of dis-nogamycin. 7-con-O-Methylnogarol was most lethal to cells in early G1, S, and G2. Only cells in mid- and late G1 were much less sensitive to this drug.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7438031

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  A phase II study of menogaril (NSC-269148) in colorectal carcinoma. A Southwest Oncology Group study.

Authors:  R P Whitehead; R H Earhart; T Fleming; P Goodman; J S Macdonald; T Pollock; J S Ungerleider
Journal:  Invest New Drugs       Date:  1990-08       Impact factor: 3.850

2.  Menogaril: a new anthracycline agent entering clinical trials.

Authors:  J P McGovren; K G Nelson; M Lassus; J C Cradock; J Plowman; J P Christopher
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

3.  Menogaril in the treatment of malignant mesothelioma: a phase II study.

Authors:  C A Hudis; D P Kelsen
Journal:  Invest New Drugs       Date:  1992-07       Impact factor: 3.850

4.  Synergistic combination of menogarol and melphalan and other two drug combinations.

Authors:  B K Bhuyan; E G Adams; M Johnson; S L Crampton
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

5.  P388 leukaemia cells resistant to the anthracycline menogaril lack multidrug resistant phenotype.

Authors:  G J Badiner; B C Moy; K S Smith; W G Tarpley; V E Groppi; B K Bhuyan
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

6.  A comparison of adriamycin and mAMSA in vitro: cell lethality and SCE studies.

Authors:  C West; I J Stratford; N Barrass; E Smith
Journal:  Br J Cancer       Date:  1981-12       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.